Clinical Trial Update: Study to Estimate Efficacy of Combining Dostarlimab and Niraparib in Relapsed EOC After Treatment With PARPi [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating dostarlimab plus niraparib for relapsed ovarian, fallopian tube, or primary peritoneal cancer has been withdrawn. The study targeted …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fallopian Tube Cancer
• Ovarian Cancer
• Peritoneal Cancer

Drugs mentioned

• Dostarlimab (dostarlimab)
• Niraparib (Niraparib)

Snippet

Sponsor: AGO Research GmbH | Conditions: Recurrent Ovarian Cancer, Recurrent Fallopian Tube Cancer | Phase 2 | Status: WITHDRAWN